Patrick M. Jedlowski

Dermatology

5190 E Farness Dr Ste 110
Tucson, AZ 85712

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System (FAERS).

Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System (FAERS).

Journal: The Australasian journal of dermatology

Published: September 15, 2025

TNF-α Inhibitor Associated Psoriasis in Rheumatoid Arthritis and Inflammatory Bowel Disease Patients: A Disproportionality Analysis Using the FDA Adverse Event Reporting System.

TNF-α Inhibitor Associated Psoriasis in Rheumatoid Arthritis and Inflammatory Bowel Disease Patients: A Disproportionality Analysis Using the FDA Adverse Event Reporting System.

Journal: Journal of cutaneous medicine and surgery

Published: June 08, 2025

Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System.

Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System.

Journal: Melanoma research

Published: December 10, 2024

Erythema multiforme associated with the immune checkpoint inhibitors: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System.

Erythema multiforme associated with the immune checkpoint inhibitors: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System.

Journal: Journal of the American Academy of Dermatology

Published: May 31, 2024

Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023.

Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 29, 2024

Medication Associations With Severe Cutaneous Adverse Reactions: A Case/Non-Case Analysis Using the FDA Adverse Event Reporting System.

Medication Associations With Severe Cutaneous Adverse Reactions: A Case/Non-Case Analysis Using the FDA Adverse Event Reporting System.

Journal: Journal of cutaneous medicine and surgery

Published: January 08, 2024

Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.

Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.

Journal: The Australasian journal of dermatology

Published: November 19, 2023

Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system.

Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 20, 2023

Use of fractionated laser therapy for the treatment of androgenetic alopecia: a systematic review and meta-analysis.

Use of fractionated laser therapy for the treatment of androgenetic alopecia: a systematic review and meta-analysis.

Journal: Lasers in medical science

Published: April 05, 2023

Annular plaques and nodules at vaccination sites in an infant.

Annular plaques and nodules at vaccination sites in an infant.

Journal: Pediatric dermatology

Published: January 19, 2023

Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).

Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).

Journal: Journal of cutaneous medicine and surgery

Published: December 10, 2022

Association of Nonmelanoma Skin Cancers, Melanoma, and Merkel Cell Carcinoma with Dermatologic Medications: A Case-Control Pharmacovigilance Study of the FDA Adverse Events Reporting System.

Association of Nonmelanoma Skin Cancers, Melanoma, and Merkel Cell Carcinoma with Dermatologic Medications: A Case-Control Pharmacovigilance Study of the FDA Adverse Events Reporting System.

Journal: Dermatology (Basel, Switzerland)

Published: November 17, 2022

Showing 1-12 of 35

Last Updated: 09/26/2026